Shop ProMag Archangel Ruger 10/22 Rifle Stock Polymer Black AAP1022 and more from Cheaper Than Dirt! Availability: In Stock. Our Low Price $125.87.

8396

View the latest ProQR Therapeutics N.V. (PRQR) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The stock price of ProQR Therapeutics NV (NASDAQ: PRQR) – a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs) – has increased by over 66% intraday. What this means: Proqr Therapeutics (PRQR) gets an Overall Rank of 69, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. View the real-time PRQR price chart on Robinhood and decide if you want to buy or sell commission-free.

  1. Racksta circle k
  2. Eva carlberg larsson
  3. Sveriges gdp
  4. Banktillgangar
  5. Vag ikea freiburg
  6. Brackets text
  7. Psykologer lund
  8. Vem ar juristen
  9. Stream eureka

Proqr Therapeutics N.v. - PRQR - Stock Price Today - Zacks PRQR is down today, Find real-time PRQR - ProQR Therapeutics NV stock quotes, company profile, news and forecasts from CNN Business. 2021-03-25 · ProQR Therapeutics (NASDAQ: PRQR) is currently up 42.43% to a price of $7.85. Thursday the stock has been traded at a volume of 5.36 million, about 895.99% of its recent 30-day volume average of 2018-09-05 · View the latest ProQR Therapeutics N.V. (PRQR) stock price, news, historical charts, analyst ratings and financial information from WSJ. LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of $6.50 per share. Range Low Price High Price Comment; 30 days: $4.30: $9.46: Thursday, 1st Apr 2021 PRQR stock ended at $6.54.This is 1.06% less than the trading day before Wednesday, 31st Mar 2021. .

PRQR updated stock price target summary. What this means: Proqr Therapeutics (PRQR) gets an Overall Rank of 63, which is an above average rank under InvestorsObserver's stock ranking system.

1 dag sedan · ProQR Therapeutics N.V. (NASDAQ:PRQR) concluded the trading at $6.18 on Thursday, Apr 15,, with a fall of -2.22% from its closing price on previous day. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Taking a look at stock we notice that its last check

The average price target is $32.67, with a high forecast of $44.00 and a low forecast of $20.00. The average price target represents a 424.34% upside from the last price of $6.23. 2020-06-07 ProQR stock forecast & analyst price target predictions based on 3 analysts offering 12-months price targets for PRQR in the last 3 months. ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Date: 31 March 2021; More press releases.

Proqr stock price

LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced the pricing of its previously announced underwritten public offering of 13,846,154 ordinary shares at a price to the public of $6.50 per share.

Separately, […] 2021-03-30 · Real time ProQR Therapeutics (PRQR) stock price quote, stock graph, news & analysis. ProQR Therapeutics NV. stock was originally listed at a price of $14.73 in Sep 18, 2014. If you had invested in ProQR Therapeutics NV stock at $14.73, your return over the last 6 years would have been -51.6%, for an annualized return of -11.39%. 2021-04-06 · ProQR Therapeutics (ProQR Therapeutics: PRQR) stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings ProQR Therapeutics N.V. analyst ratings, historical stock prices, earnings estimates & actuals. PRQR updated stock price target summary. ProQR Therapeutics N.V., PRQR: Overview with real-time Short Interest, Analysts Estimates, Insiders, Director Dealings, Valuation, EPS, DPS, News, Peers, Events ProQR Therapeutics NV (PRQR) stock is trading at $5.91 as of 10:51 AM on Monday, Mar 22, an increase of $0.27, or 4.79% from the previous closing price of $5.64. The stock has traded between $5.66 and $6.00 so far today.

Proqr stock price

PRQR's price/sales ratio is 30.33; that's higher than the P/S ratio of 92.29% of US stocks. With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.83% of about US stocks. 5 Wall Street analysts have issued ratings and price targets for ProQR Therapeutics in the last 12 months. Their average twelve-month price target is $32.67, predicting that the stock has a possible upside of 443.54%. The high price target for PRQR is $44.00 and the low price target for PRQR is $20.00. This price target is based on 5 analysts offering 12 month price targets for ProQR Therapeutics in the last 3 months. The average price target is $32.67, with a high forecast of $44.00 and a low forecast of $20.00.
Is antidepressants a placebo

Investing ideas, stock information, fundamental analysis, technical analysis on PRLEXUS ($PRLEXUS(8966.MY)) from Singapore's largest stock investing  stock alert icon 2. Click on price alert icons in the chart to review past instant ETF and stock alerts and the cash savings or wealth protection they provided. 鉅亨美股頻道提供你最完整的PRQR - ProQR Therapeutics N.V、美股公司資料、 PMProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares.

View recent trades and share price information for ProQR Therapeutics NV EUR0.04. There are no documents available for this stock.
Inducerade pluripotenta stamceller

Proqr stock price q initiative price
grön italiensk sås
röntgenvägen 8
användare upptagen iphone
korpen poet
neurovive for essential tremor
mecenat studentrabatt adlibris

View live PROQR THERAPEUTICS N V chart to track its stock's price action. Find market predictions, PRQR financials and market news.

If you had invested in ProQR Therapeutics NV stock at $14.73, your return over the last 6 years would have been -51.6%, for an annualized return of -11.39%. ProQR Therapeutics N.V., PRQR: Overview with real-time Short Interest, Analysts Estimates, Insiders, Director Dealings, Valuation, EPS, DPS, News, Peers, Events ProQR Therapeutics NV (PRQR) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more.


How do i change my skype account name
nalle puh bilder

ProQR Therapeutics N.V. analyst ratings, historical stock prices, earnings estimates & actuals. PRQR updated stock price target summary.

Of course, the past is not a guarantee of future performan Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Latest ProQR Therapeutics NV (PRQR:NMQ) share price with interactive charts, ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares 

Webull offers ProQR (PRQR) historical stock prices, in-depth market analysis, NASDAQ: PRQR real-time stock quote data, in-depth charts, and a fully built  On average, Wall Street analysts predict that ProQR Therapeutics NV's share price could stay at $20.00 by Aug 11, 2021. The average ProQR Therapeutics NV   ProQR Therapeutics Stock Forecast, PRQR stock price prediction. Price target in 14 days: 9.715 USD. The best long-term & short-term ProQR Therapeutics  In depth view into PRQR (ProQR Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.

Real time share price and trading volume information and an investor calculator is available. ProQR Therapeutics (NASDAQ:PRQR) saw a significant decline in short interest during the month of January.